


What is claimed is:

1. Compounds of the formula (I):



(I)

$R_1$  is selected from the group consisting of a bond and  $C_{1-10}$  alkyl, alkenyl or alkenylene;

$R_2$  and  $R_3$  are independently selected from the group consisting of hydrogen and  $C_{1-10}$  alkyl, alkenyl or alkenylene

$R_4$  is selected from the group consisting of a bond and  $C_{1-10}$  alkyl, alkenyl or alkenylene, said  $C_{1-10}$  alkyl, alkenyl or alkenylene optionally substituted with 1-3 halogen or oxo groups;

$R_5$  is selected from the group consisting of hydrogen, a 5 or 6 membered aromatic or heteroaromatic group, and a  $C_{3-12}$  cycloalkyl;

$R_6$  is selected from the group consisting of  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl and halogen; and

$n$  is an integer from 0-3; and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 wherein  $R_1$  is selected from methyl or ethyl.
3. A compound of claim 1 wherein  $R_2$  is selected from methyl, ethyl, propyl and butyl.
4. A compound of claim 1 wherein  $R_4$  is selected from a bond, methyl or ethyl, wherein the methyl and ethyl are optionally substituted with an oxo group.
5. A compound of claim 1 wherein  $R_5$  is phenyl.

6. A compound of claim 1 selected from  
1-benzylamino-3-dibutylamino-propyl;  
1-[1-benzyl-1-(2-phenyl-1-oxo-ethyl)-amino]-2-diethylamino-ethyl;  
1-[1-benzyl-1-(2-phenyl-1-oxo-ethyl)-amino]-2-dibutylamino-ethyl; and  
pharmaceutically acceptable salts thereof.
7. A pharmaceutical composition comprising a compounds of claim 1 and at  
least one pharmaceutically acceptable excipient.
8. A method of treating pain comprising administering to a patient in need  
thereof, an effective amount of a compound according to claim 1.
9. A method of modulating a pharmacological response from the  $\mu$  receptor  
comprising administering an effective amount of a compound according to  
claim 1.
10. A method of reducing side effects associated with the administration of opioid  
analgesics in a human patient comprising administering to said human patient  
an analgesically effective amount of a non-opioid compound which exhibits a  
binding affinity specificity for the  $\mu$  receptor as compared to the  $\delta_2$  receptor  
( $K_i$  (nM) at the  $\delta_2$  receptor/  $K_i$  (nM) at the  $\mu$  receptor) of greater than about  
250.